Richard Gonzalez, AP Images

Ab­b­Vie sees a megablock­buster in Vray­lar. Could a new de­pres­sion in­di­ca­tion push peak sales past $4B?

De­spite a bumpy take­off, Ab­b­Vie has some big plans for Vray­lar, the block­buster schiz­o­phre­nia and bipo­lar drug it snapped up from Al­ler­gan a cou­ple of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.